Because of the role of IL-12 in driving colon inflammation during the early stages of IBD and the subsequent shift toward an IL-23–dependent inflammatory response contributing to disease chronicity (48), it is indicated that anti–IL-23p19 antibodies may be more effective in the later stages of IBD (49). The gene discussed is IL23A; the disease is inflammatory bowel disease.